IMVT net incomeQ2 2027-$97.25M
IMVT net income was -$97.25M in fiscal Q2 2027 (ended Sep 30, 2026), compared with -$126.50M a year earlier. For the full fiscal 2026 it was -$505.61M, compared with -$413.84M in fiscal 2025.
Immunovant Inc. (IMVT) financials
For the twelve months ended Sep 30, 2026, Immunovant Inc. reported -$508.96M of net income.
- Net income, TTM
- -$508.96M
- EPS, diluted, TTM
- -$2.55
- Cash
- $722.27M
- Market cap
- $7.26B
FY2019FY2026
FY2019FY2026
IMVT revenue and earnings growth
IMVT EPSQ2 2027-$0.47
IMVT diluted EPS was -$0.47 in fiscal Q2 2027 (ended Sep 30, 2026), compared with -$0.73 a year earlier. For the full fiscal 2026 it was -$2.77, compared with -$2.73 in fiscal 2025.
IMVT free cash flowQ4 2026-$95.07M
IMVT free cash flow was -$95.07M in fiscal Q4 2026 (ended Mar 31, 2026), compared with -$110.84M a year earlier. For the full fiscal 2026 it was -$407.32M, compared with -$376.63M in fiscal 2025.
Income statement
| Line item | Mar 31, 2026 | Mar 31, 2025 | Mar 31, 2024 | Mar 31, 2023 | Mar 31, 2022 | Mar 31, 2021 | Mar 31, 2020 | Mar 31, 2019 |
|---|---|---|---|---|---|---|---|---|
| Research and development | $456.66M | $360.92M | $212.93M | $160.26M | $101.81M | $68.60M | $47.93M | $25.73M |
| Selling, general and admin | $76.24M | $77.23M | $57.28M | $48.02M | $54.23M | $39.51M | $18.15M | $2.69M |
| Interest expense | - | - | - | - | - | $0 | $625.0K | - |
| Pre-tax income | -$505.39M | -$412.95M | -$258.77M | -$210.95M | -$156.81M | -$107.79M | -$66.29M | -$28.58M |
| Income tax | $215.0K | $891.0K | $567.0K | $9.0K | -$84.0K | -$358.0K | $97.0K | $19.0K |
| Net income | -$505.61M | -$413.84M | -$259.34M | -$210.96M | -$156.73M | -$107.43M | -$66.39M | -$28.60M |
| EPS, basic | -$2.77 | -$2.73 | -$1.88 | -$1.71 | -$1.43 | -$1.22 | -$1.54 | -$1.29 |
| EPS, diluted | -$2.77 | -$2.73 | -$1.88 | -$1.71 | -$1.43 | -$1.22 | -$1.54 | -$1.29 |
| Diluted shares | 182.4M | 151.6M | 138.1M | 123.1M | 109.7M | 87.8M | 43.2M | 22.2M |
Balance sheet
| Line item | Mar 31, 2026 | Mar 31, 2025 | Mar 31, 2024 | Mar 31, 2023 | Mar 31, 2022 | Mar 31, 2021 | Mar 31, 2020 | Mar 31, 2019 |
|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $902.11M | $713.97M | $635.37M | $376.53M | $493.82M | $400.15M | $100.57M | $6.99M |
| Receivables | $1.13M | $2.08M | $5.34M | $700.0K | $12.23M | $596.0K | - | - |
| Current assets | $948.82M | $767.66M | $665.77M | $404.33M | $512.93M | $409.01M | $109.08M | $12.58M |
| Total assets | $957.01M | $776.22M | $666.37M | $405.84M | $515.56M | $412.49M | $109.39M | $13.83M |
| Current liabilities | $104.42M | $68.78M | $48.61M | $43.30M | $44.52M | $18.77M | $15.32M | $300.4K |
| Total liabilities | $104.42M | $68.78M | $48.61M | $43.34M | $45.74M | $21.01M | $15.32M | $6.49M |
| Shareholders' equity | $852.59M | $707.45M | $617.76M | $362.49M | $469.82M | $391.48M | $94.07M | $7.34M |
Cash flow
| Line item | Mar 31, 2026 | Mar 31, 2025 | Mar 31, 2024 | Mar 31, 2023 | Mar 31, 2022 | Mar 31, 2021 | Mar 31, 2020 | Mar 31, 2019 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$407.31M | -$375.87M | -$214.23M | -$188.19M | -$106.11M | -$83.33M | -$53.36M | -$28.55M |
| Capital expenditures | $8.0K | $759.0K | $360.0K | $197.0K | $254.0K | $210.0K | $31.0K | $52.0K |
| Free cash flow | -$407.32M | -$376.63M | -$214.59M | -$188.39M | -$106.37M | -$83.54M | -$53.39M | -$28.60M |
| Investing cash flow | -$8.0K | -$759.0K | -$360.0K | -$197.0K | -$254.0K | -$210.0K | -$31.0K | -$52.0K |
| Financing cash flow | $595.76M | $454.49M | $472.43M | $70.89M | $200.13M | $383.11M | $146.97M | $35.58M |
| Stock-based compensation | $55.72M | $49.49M | $41.12M | $32.30M | $34.24M | $18.82M | $6.96M | $1.31M |
Key ratios
| Line item | Mar 31, 2026 | Mar 31, 2025 | Mar 31, 2024 | Mar 31, 2023 | Mar 31, 2022 | Mar 31, 2021 | Mar 31, 2020 | Mar 31, 2019 |
|---|---|---|---|---|---|---|---|---|
| Return on equity | -59.3% | -58.5% | -42.0% | -58.2% | -33.4% | -27.4% | -70.6% | -389.7% |
| Return on assets | -52.8% | -53.3% | -38.9% | -52.0% | -30.4% | -26.0% | -60.7% | -206.8% |
| Current ratio | 9.09 | 11.16 | 13.70 | 9.34 | 11.52 | 21.79 | 7.12 | 41.87 |
Income statement
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Research and development | $85.01M | $142.63M | $142.29M | $98.92M | $114.25M | $101.20M | $93.65M | $94.52M | $97.27M | $75.47M | $66.06M | $48.34M |
| Selling, general and admin | $19.14M | $17.69M | $17.27M | $15.44M | $17.51M | $26.02M | $20.17M | $19.78M | $18.47M | $18.81M | $14.82M | $13.21M |
| Pre-tax income | -$97.25M | -$153.22M | -$150.70M | -$109.08M | -$125.91M | -$119.70M | -$105.87M | -$110.97M | -$109.04M | -$87.07M | -$75.09M | -$51.53M |
| Income tax | $0 | $0 | -$2.84M | $1.55M | $594.0K | $913.0K | $583.0K | $152.0K | $78.0K | $77.0K | $232.0K | -$108.0K |
| Net income | -$97.25M | -$153.22M | -$147.86M | -$110.64M | -$126.50M | -$120.61M | -$106.45M | -$111.12M | -$109.12M | -$87.15M | -$75.32M | -$51.42M |
| EPS, basic | -$0.47 | -$0.75 | -$0.72 | -$0.61 | -$0.73 | -$0.71 | -$0.63 | -$0.76 | -$0.74 | -$0.60 | -$0.50 | -$0.36 |
| EPS, diluted | -$0.47 | -$0.75 | -$0.72 | -$0.61 | -$0.73 | -$0.71 | -$0.63 | -$0.76 | -$0.74 | -$0.60 | -$0.50 | -$0.36 |
| Diluted shares | 206.7M | 205.5M | - | 181.5M | 173.6M | 170.9M | - | 146.9M | 146.5M | 146.1M | - | 144.5M |
Balance sheet
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $722.27M | $797.80M | $902.11M | $994.52M | $521.87M | $598.91M | $713.97M | $374.69M | $472.94M | $560.00M | $635.37M | $690.94M |
| Receivables | $138.0K | $697.0K | $1.13M | $1.64M | $1.97M | $1.94M | $2.08M | $2.22M | $1.88M | $2.42M | $5.34M | $1.03M |
| Current assets | $760.05M | $851.18M | $948.82M | $1.04B | $573.55M | $651.76M | $767.66M | $412.54M | $507.37M | $589.05M | $665.77M | $710.78M |
| Total assets | $760.97M | $852.49M | $957.01M | $1.05B | $582.96M | $661.44M | $776.22M | $420.93M | $515.71M | $589.68M | $666.37M | $711.45M |
| Current liabilities | $104.02M | $117.10M | $104.42M | $66.26M | $63.25M | $52.90M | $68.78M | $68.31M | $66.65M | $45.02M | $48.61M | $32.10M |
| Total liabilities | $104.02M | $117.10M | $104.42M | $66.26M | $63.25M | $52.90M | $68.78M | $68.31M | $66.65M | $45.02M | $48.61M | $32.10M |
| Shareholders' equity | $656.95M | $735.39M | $852.59M | $986.13M | $519.71M | $608.54M | $707.45M | $352.62M | $449.05M | $544.66M | $617.76M | $679.34M |
Cash flow
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$83.22M | -$124.41M | -$95.06M | -$92.33M | -$102.52M | -$117.41M | -$110.64M | -$100.39M | -$88.65M | -$76.20M | -$59.70M | -$47.10M |
| Capital expenditures | - | - | $8.0K | $0 | $0 | $0 | $201.0K | $180.0K | $196.0K | $182.0K | $150.0K | $131.0K |
| Free cash flow | - | - | -$95.07M | -$92.33M | -$102.52M | -$117.41M | -$110.84M | -$100.57M | -$88.84M | -$76.38M | -$59.85M | -$47.23M |
| Investing cash flow | - | - | -$8.0K | $0 | $0 | $0 | -$201.0K | -$180.0K | -$196.0K | -$182.0K | -$150.0K | -$131.0K |
| Financing cash flow | $7.88M | $20.10M | $3.64M | $564.60M | $24.59M | $2.92M | $450.61M | $2.46M | $730.0K | $686.0K | $1.54M | $469.84M |
| Stock-based compensation | $13.28M | $13.77M | $11.14M | $12.71M | $13.36M | $18.51M | $11.69M | $11.65M | $12.69M | $13.46M | $9.68M | $10.22M |
Key ratios
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current ratio | 7.31 | 7.27 | 9.09 | 15.74 | 9.07 | 12.32 | 11.16 | 6.04 | 7.61 | 13.08 | 13.70 | 22.14 |
Source: XBRL data Immunovant Inc. files with the SEC, latest filing dated Nov 9, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.
Per-share figures are as filed. The filings show no stock split in these periods.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
IMVT peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| IMVT | - | - | -$508.96M | - | $7.26B |
| AMGN | $38.90B | +8.2% | $9.39B | 24.1% | $251.65B |
| GILD | $30.99B | +6.5% | -$3.86B | -12.5% | $210.01B |
| MRNA | $2.52B | +13.1% | -$2.79B | -110.5% | $107.39B |
| ARGX | $4.25B | +88.6% | $1.29B | 30.4% | $59.72B |
| RVMD | $0 | - | -$1.13B | - | $43.29B |
| BIIB | $10.30B | +2.3% | $347.50M | 3.4% | $37.67B |
| BNTX | €2.87B | +4.3% | -€1.14B | -39.6% | $21.98B |
| EXEL | $2.50B | +9.1% | $885.14M | 35.5% | $17.51B |
IMVT FAQ
5 questionsIs IMVT profitable?
No. Immunovant Inc. reported a net loss of $508.96M for the twelve months ended Sep 30, 2026.How much cash and debt does IMVT have?
Immunovant Inc. reported $722.27M in cash and cash equivalents on its most recent balance sheet in SEC filings.What is IMVT earnings per share?
Diluted earnings per share were -$2.55 for the twelve months ended Sep 30, 2026, from SEC filings, restated for any stock split those filings show.When did IMVT last report financial results?
The latest statements here come from Immunovant Inc.'s 10-Q filed on Nov 9, 2026, covering the period ended Sep 30, 2026.Where does this IMVT financial data come from?
Quantisnow builds these statements from the structured XBRL data Immunovant Inc. files with the SEC. It is provided for information only and is not investment advice.